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Introduction
Prostate cancer is the most common cancer in men
and the second highest cause of cancer-related
mortality in the U.K. Family history is the strongest risk
factor for prostate cancer. A man with one close
relative (such as a father or a brother) with prostate
cancer has twice the risk of developing prostate cancer
as a man with no family history. If two close male
relatives (such as a brother and a father) are affected,
a man’s lifetime risk of developing prostate cancer is
increased fivefold. The degree of relative risk and the
increase in its magnitude can be explained by
a genetic effect in, at least, a component of the
predisposing factors to this disease. It is now becoming
clear that the identification of mutations in candidate
prostate cancer predisposition genes is proving more
difficult to be made than the identification of
susceptibility genes for some other common cancers
such as breast, ovary, and colon cancer. 
Abstract
Prostate cancer is the most common cancer in men and the second highest cause of cancer-related mortality
in the U.K. A genetic component in predisposition to prostate cancer has been recognized for decades. One
of the strongest epidemiological risk factors for prostate cancer is a positive family history. The hunt for the genes
that predispose to prostate cancer in families has been the focus of many research groups worldwide for the
past 10 years. Both epidemiological and twin studies support a role for genetic predisposition to prostate cancer.
Familial cancer loci have been found, but the genes that cause familial prostate cancer remain largely elusive. 
Unravelling the genetics of prostate cancer is challenging and is likely to involve the analysis of numerous predisposition
genes. Current evidence supports the hypothesis that excess familial risk of prostate cancer could be due to the
inheritance of multiple moderate-risk genetic variants. Although research on hereditary prostate cancer has improved
our knowledge of the genetic aetiology of the disease, a lot of questions still remain unanswered. 
This article explores the current evidence that there is a genetic component to the aetiology of prostate cancer
and attempts to put into context the diverse findings that have been shown to be possibly associated with the
development of hereditary prostate cancer. Linkage searches over the last decade are summarised. It explores
issues as to why understanding the genetics of prostate cancer has been so difficult and why despite this, it is
still a major focus of research. Finally, current and future management strategies of men with Hereditary Prostate
Cancer (HPC) are discussed. 
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This difficulty of prostate cancer predisposition gene
identification could be for several reasons. Firstly,
prostate cancer is diagnosed at a late age, thus often
making it impossible to obtain DNA samples from living
affected men for more than one generation. This makes
linkage in large pedigrees difficult. Secondly, the
presence within high-risk pedigrees of phenocopies
(those with prostate cancer, but without the genetic
alteration) weakens the linkage results. Finally, the
genetic heterogeneity of this complex disease (the fact
that different pedigrees may be due to different genes)
and the uncertainty of the optimal genetic model could
result in inaccurate linkage results which make gene
identification difficult. 
Significant linkage in familial prostate cancer was
first published in 1996. A group from Johns Hopkins
University, USA [1] reported linkage at a locus on
chromosome 1q24-25, which was named Hereditary
Prostate Cancer 1 (HPC1). Since then, several large
linkage studies have been conducted, and the results
of many different groups have revealed new loci and
challenged others [2-5]. 
To date, work on prostate cancer linkage has
reported genotyping data in over 1600 families. There
are numerous conflicting reports reporting or refuting
linkage within many areas in the genome, and this
challenges our understanding of the genetic basis of
this disease. This is disparate from the search for
a familial breast cancer predisposition gene in which
analysis of linkage in select regions revealed a site
where the BRCA1 gene was situated [6]. This shows
that genetic predisposition to prostate cancer is highly
complex probably involving numerous predisposition
genes and that a high proportion of high-risk families
may not be due to a single high-risk gene.
Conventional linkage may not be the optimal method
of predisposition gene identification in this disease
because of genetic heterogeneity where different
familial clusters are due to different genes. 
Current body of evidence for the genetic
aetiology of prostate cancer 
Epidemiological evidence
In the 1950-60s, it was observed that the risk of
prostate cancer in relatives of sufferers was higher [7,
8]. Large families have been observed in which prostate
cancers seemed to cluster. Early observations were made
in large families collected and studied in Utah [9, 10].
To explore the evidence of a familial component, case
control, cohort and twin studies have been reported. 
Case-control studies
The case-control studies can be split into two simple
types. The first type compares prostate cancer incidence
in first-degree relatives of prostate cancer patients (cases)
with the incidence in relatives of cancer-free individuals
(controls). The second type compares the percentage of
prostate cancer cases vs. controls with a positive family
history of the disease [7-9, 11-26]. These studies
indicated that the relative risks (RR) amongst first-degree
relatives of affected individuals range from 0.64 to
11.00-fold [27-29]. With the exception of the RR of 0.64
[11], in a study which was done on a small sample set
of 39 families, 15 of these 16 studies reported a RR of
1.76 or higher. The RR increases further when more than
one relative is affected. Steinberg et al, 1990, [15]
showed that the RR with an affected first-degree relative
was 2.0, with a second-degree relative was 1.7, but with
both first- and second-degree relatives combined, RR
rose markedly, to 8.8. In addition to this, they observed
that the RR increased as the number of family members
increased, with RRs of 2.2, 4.9 and 10.9 for 1, 2 and
3 additional affected relatives besides the proband,
respectively [15]. This is all strong evidence for the
involvement of a genetic component in familial disease
as these increases in RR are too large to be accounted
for solely by an environmental effect. Further evidence
of a genetic effect is shown by the observation that the
RR to relatives increases as the age of the proband
decreases [9, 30]. A brother of a proband with prostate
cancer at the age of 50 has a 1.9-fold higher risk of
developing prostate cancer compared with a brother of
a man diagnosed with the disease at the age of 70 [30]. 
Cohort studies
Cohort studies attempt to avoid possible bias by
focussing on an unselected population. Goldgar et al
[31] showed a familial prostate cancer RR of 2.21 in
first-degree relatives of 6,350 probands from an
unselected population from the Utah Population
Database. Similarly Gronberg et al [32] found an RR
of 1.70 from their study involving 5,496 sons of
Swedish men from Cancer Registry data. 
Twin studies
These show that there is an increased RR in mono-
compared with di-zygotic twins of just over 3- to 6-fold
[33]. Page et al [34] studied 15,924 male twin pairs
and found pair wise concordance (twin pairs where both
men were affected) rates amongst monozygotic twins
was 15.7% whilst for dizygotic twins the frequency was
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3.7% (p=<0.001). Proband wise concordance (number
of concordant affected twins divided by total no of
affected twins) was 27.1% for monozygotic twins and
7.1% for dizygotic twins, which gives a risk ratio of 3.8.
Similar results were noted in Finland [35]. Another study
concluded that up to 42% of prostate cancer risk could
be attributable to heritable factors [36]. The absolute
risk of prostate cancer for twins diagnosed up to the
age of 75 was sixfold higher for mono- vs. di-zygotic
twins (18% vs. 3%). It also showed a statistically
significant shorter time interval between age at diagnosis
times for monozygotic twins compared with dizygotic
twins (5.7 yrs vs. 8.8 years; p=0.04). 
Segregration analyses 
Segregation analyses study the structure of familial
clusters and describe the mode of inheritance,
age-specific cumulative risk (penetrance), and allele
frequency of genetic predisposition to a disease. Carter
et al [30], using such analyses, suggested that prostate
cancer diagnosed at <55 years may be due to a rare
autosomal dominant highly penetrant allele which
could account for up to 43% of disease in this age
group and up to 9% of prostate cancer in men aged
up to 85 years. Alleles for such a rare autosomal
dominant gene were predicted to exist at a frequency
of 0.003 and to cause a cumulative risk of disease of
88% by the age of 85 years compared with 5% for
non-carriers. Other reports have reached similar
conclusions, but with a commoner allele frequency and
a lower penetrance of about 67% (Gronberg et al [32],
allele frequency 0.0167; Schaid et al [37], allele
frequency 0.006). A recessive or X-linked model is
suggested by some studies which noted higher risks to
brothers of prostate cancer cases compared with fathers
[38, 39]. Ewis et al (2002) [40] report an odds ratio
of 2.04 (p=0.02) for allele C of dYs19 in Japanese
prostate cancer patients, whilst other alleles of this
region were protective (allele D, OR 0.26 p=0.002).
The Y chromosome (father to son transmission) is
therefore also implicated. It is possible that a mixture
of several models exist giving rise to age-related risks
[41]. Dominantly inherited risk allele(s) may explain
early onset disease and a recessive or X-linked model
could account for its later onset [42]. 
Molecular analysis evidence 
– linkage studies [genome wide scans]
Linkage analysis involves a gene-hunting technique
that looks for co-segregation of a disease in large,
high-risk families, with disease-causing genetic
mutations. Linkage analysis has been used to map
many familial cancer loci e.g. colorectal cancer,
breast/ovarian cancer, and melanoma reviewed in
Eeles et al, 1996 [43]. Initially, linkage analysis narrows
down the region within which a disease-causing locus
may lie by analysing co-inheritance of polymorphic
stretches of DNA such as microsatellite markers. The
sequencing of the human genome will also make the
use of single nucleotide polymorphisms (SNPs) possible
and as these are more numerous than polymorphic
runs of DNA sequence. These will enable denser
linkage maps to be determined. Once a region of
linkage is identified then candidate gene mutation
analysis within the region is undertaken to identify the
disease-causing mutation. 
Candidate gene analysis evidence 
– BRCA2, NBS and CHEK2 genes
The search for genetic markers of disease susceptibility
often utilizes the candidate gene approach, where a gene
is targeted based on the properties and metabolic
pathways of its protein product. In the early nineties,
prostate cancer cases were noted to be clustered within
breast cancer families [44, 45]. The RR of prostate cancer
in male carriers of mutations in the breast cancer
predisposition genes BRCA1 and BRCA2 is increased.
The RR with respect to BRCA1 was found to be 3.33 [46]
and 1.82 in a further analysis by the BCLC [47]. That of
BRCA2 was found to be 4.65. The RR is higher in men
with prostate cancer diagnosed before 65 years (RR
7.33), with an estimated cumulative incidence by the age
of 70 of 7.5-33.0%. A founder mutation 999del5 in
BRCA2 has been identified in Iceland. This mutation is
reported to confer a cumulative prostate cancer risk to
carriers of 7.6% by the age of 70 [48]. Sixty seven percent
of men who had the mutation all developed advanced
prostate cancer and a high mortality [49], raising the
possibility that BRCA2 predisposes to more aggressive
disease. A report in a Swedish family carrying the BRCA2
mutation 6051delA [50] adds weight to the evidence that
such mutations are pathogenic. A mutation screen of
BRCA1 and BRCA2 genes was conducted by Gayther et
al [51] in a set of 38 UK families. Two germline
deleterious BRCA2 mutations were observed. A further
study was conducted by Edwards et al [52] on 263 men
aged <55 at diagnosis. The six pathogenic mutations
found were interestingly outside the ovarian cancer cluster
region in the gene, implying a genotype/phenotype
correlation and accounted for 2% of prostate cancer at
this young age. This equated to an RR of 23 by the age
of 60 and conferred an absolute risk of prostate cancer
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by the age of 55 of 1.3% and 10% by the age of 65.
This supports the claim that BRCA2 is a high-risk prostate
cancer gene. Two recent studies have reported an
increased risk of prostate cancer associated with the
Ashkenazi founder mutations in the BRCA genes, lending
further evidence to these data [53, 54]. 
Subsequent to these reports, germline mutations have
been found in the NBS gene in the Slavic population at
a higher frequency in prostate cancer cases than controls
[55] and in the CHEK2 gene [56]. This raises the
possibility that prostate cancer predisposition may in some
cases be due to mutations in genes in the DNA repair
pathway that in the homozygous form give rise to a severe
phenotype (in the case of BRCA2 this would be Fanconi’s
anaemia D2 and in the case of NBS would be Nijmegen
Breakage Syndrome), but in the heterozygous form,
would give a risk of prostate cancer. 
Genome searches in prostate cancer
The process of running a large number of
microsatellites – typically in the region of 400, has many
terms: Genome wide Scan, Genome wide Search or
Genome wide Screen – and can conveniently be
abbreviated to GWS. Numerous linkage analysis
experiments have been undertaken across the genome
to identify prostate cancer susceptibility loci. The ACTANE
(Anglo-Canadian-Texan-Australian-Norwegian-EU
Biomed) group has used a definition of age at onset
and number of cases, but has also concentrated on the
collection of clinically significant disease. This is because
the disease manifests 10 years later on average than
PSA-detected disease and therefore men with early onset
clinically detected disease would have had a raised PSA
level at even earlier age and may therefore be enriched
for genetic predisposition [28]. 
Thus far, several GWS have been reported for
prostate cancer. [1, 3, 5, 57-72]. The significant results
are summarised as follows: 
1q23-24: HPC1 and the RNASEL data. The first
GWS identified a locus named HPC1 (Hereditary
Prostate Cancer 1) at 1q24-25. A group from Johns
Hopkins University, Baltimore, conducted the study in
91 North American and Swedish families and their
report suggested that 34% of families may be linked
to this locus [1]. Various groups have since either
confirmed [73-76], or refuted [57, 58, 60, 64, 77,
78] the original observation. Goode et al [64], and
Goddard et al [79] found evidence of linkage in
families with more aggressive prostate cancer. 
A meta analysis conducted by Xu et al [80]
representing many groups, comprising the International
Consortium for Prostate Cancer Genetics (ICPCG),
reported data obtained on 772 families and found that
a lower estimate of 6% of all families were linked to
1q24-25. A more refined analysis concluded that HPC1
may play a role in a subset of families with numerous
young onset cases, particularly among black men.
Carpten et al [81] subsequently found mutations in the
cell proliferation and apoptosis regulating gene RNASEL
which was in this region. Of 8 families that were linked
to the 1q region, two had germline mutations, one was
a stop Glu265Ter (E265X) termination codon but the
other was a missense mutation. Neither segregated with
the disease. Some, but not all further reports have shown
RNASEL mutations to be associated with prostate cancer,
but with a much lower relative risk than would be
predicted by the linkage evidence. Rokman et al [82]
showed that the Glu265X in RNASEL was present 4.5-
fold more often in affected family members compared
with controls. Other groups have found that RNASEL may
confer much smaller prostate cancer risks or have found
no mutations at all in prostate cancer cases, therefore it
is not a highly penetrant prostate cancer gene which is
in conflict with the linkage evidence [83, 84]. This
suggests that the linkage results are misleading or that
a highly penetrant HPC1 exists but is still to be found. 
Other loci and candidates from GWS. Other loci
follow a similar pattern as described above i.e. loci
are identified that have significant LOD scores and
candidate genes have mutations described therein
which are then refuted, or whose risks fall on further
detailed scrutiny [85, 86]. 
Other significant loci:
PCaP (1q42.2-43; Berthon et al [57]) – this was a locus
identified in the German/French population, but not
confirmed by other groups. CAPB (1p36; Gibbs et al.
[59]) – a locus associated with primary brain tumour
and prostate cancer which on further analysis was
probably more associated with young onset prostate
cancer rather than brain tumour [87]. A locus has been
described on chromosome 16q in sibling pairs by
Suarez et al [58], and one on 20q (HPC20) by Berry et
al [63]. These are still to be confirmed. A further locus
has been described on the long arm of chromosome
X (HPCX; Xq27-28) by Xu et al [88]). This has been
confirmed by some other groups, but the gene has not
yet been identified. There are also loci that have been
found to be associated with more aggressive disease
e.g. 7q, 19q [89-91]. Eight GWS have been published
recently in one issue of the Prostate (ACTANE
Consortium [72]; Lange et al [65]; Schleutker et al [66];
Cunningham et al [67]; Xu et al [68]; Wiklund et al
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[69]; Janer et al [70]; Witte et al [71], Dec 2003).
A summary of these was published in an accompanying
review by Easton (2003) [5]. The conclusion of these
GWS to date is that there are numerous loci suggested
by the GWS from various groups which are not
consistently replicated by independent groups on study
of further prostate cancer families. This implies that there
is considerable genetic heterogeneity. 
Low penetrance genes. The possibility that a disease
is due to a combination of low penetrance, more
common genetic variants may be entertained when
large families are rare and it is difficult to locate
predisposition genes by linkage. Candidate studies of
polymorphisms are presently underway in prostate
cancer and there is currently no uniform pattern of
polymorphisms which confers increased risk from the
data. However, the most consistent polymorphisms to
date that confer a moderately increased risk are in the
SRD5A2, GSTP1 and the AR genes, [92-102]. 
Optimising prostate cancer predisposition
gene discovery in the near future 
– issues to be addressed
The are several uncertainties in the area of genetic
predisposition which are currently taxing researchers in
this area. These include (a) what is the optimal genetic
model? (b) are there different predisposition genes in
different populations? and (c) how much agreement is
there between various groups for the putative loci? The
results of future large scale multicentre studies will
potentially answer these questions. 
Combining data. It is possible that the studies
undertaken thus far are underpowered, and pooling of
data may improve the chances of finding the true
underlying linkage. This is the aim of the creation of
groups such as ICPCG. Groups undertaking linkage
analyses worldwide collaborate within this consortium. In
2000, via a meta-analysis, this group found that the 1q24
locus may contribute to about 6% of prostate cancer
families and was more common in larger prostate cancer
clusters whose average age of onset was <65 years [80]. 
Clinical vs. Screen Detected Disease. Current data
suggest that progression to clinical disease is more
likely following a raised PSA and occurs a median time
of 10 years after the PSA has risen [103]. In theory,
patients in families that are diagnosed with clinically
detected disease may have different genes to those
involved in PSA screen detected patients. At present,
whether this is true, this is unknown. 
Genetic heterogeneity for linkage: more than one
prostate cancer predisposition gene. The fact that 2% of
early onset cases have deleterious mutations in the
BRCA2 gene and that a further small percentage is due
to NBS and CHEK2 mutations and yet models suggest
that up to 43% of such cases may harbour
a predisposition gene [30], indicates that there are further
prostate cancer susceptibility genes to be discovered. 
Many instead of one prostate cancer predisposition
gene per family. In an age when the majority of
monogenic human disease genes have been identified,
a particular challenge for the coming generation of
human geneticists will be resolving complex polygenic
and multifactorial diseases. It is likely that the majority
of genetic predisposition to prostate cancer will follow
this model. 
Current clinical management concepts 
in hereditary prostate cancer
The question of whether a genetic change
influencing prostate cancer causation is associated with
factors altering treatment response needs to be
addressed. Recent reports are conflicting. Carefully
documented multi-institutional, prospective family
history data collection and outcome analysis are vital
to optimising our understanding of this condition. The
current management issues surrounding hereditary
prostate cancer (HPC) involve several components: (i)
the degree of biological aggressiveness of HPC, (ii)
whether HPC is an independent predictor of treatment
outcome, (iii) whether there is a difference in the
survival curves between sporadic and HPC and (iv) the
outcome patterns in those patients treated with radical
prostatectomy vs. radiotherapy by family history. 
Determining the degree of biological aggressiveness
Walsh initially observed that there was no significant
difference between phenotypes of sporadic, familial
and HPC undergoing radical prostatectomy with
respect to clinical stage, pre-op PSA, PSA density,
prostate weight, Gleason score, pathologic stage or
tumour histology [104]. This was later challenged by
the observation that patients with localized prostate
cancer who reported a positive family history may have
a worse outcome at three and five years following either
radiation therapy or surgery than those with sporadic
cancers [105]. This was then again refuted by three
further studies which found no difference in the
aggressiveness of HPC versus sporadic disease [106-
108]. This area therefore remains controversial. 
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Is HPC an independent predictor of treatment outcome? 
Kupelian et al [108] first demonstrated that the
presence of a family history of prostate cancer
correlates with treatment outcome in a large unselected
series of patients and suggested that familial prostate
cancer may have a more aggressive course than
nonfamilial prostate cancer. Further studies are
currently underway to validate this finding. 
Survival differences between sporadic and HPC
No significant differences in either overall or
cause-specific survival were found between sporadic,
familial, and HPC patients [109]. At present it seems
plausible that treatment plans should not differ based
on presence or absence of familial prostate cancer,
but further work is needed to substantiate this. 
Should men with a family history of prostate cancer 
be treated rather than observed? 
Based on the current body of evidence there seems
to be a rationale for genetic screening of men at risk
once genes responsible for prostate cancer are
identified. The American Urological Association
recommends that men who are at high risk for
developing prostate cancer such as men with a family
history of the disease, or men of African-American
descent begin receiving routine prostate cancer
screening at the age of 40 [110]. The American
Cancer Society recommends that men receive PSA or
digital rectal examination testing annually at the age
of 50, or earlier if they have a family history of the
disease or are of African-American descent [111]. 
Outcome patterns in HPC men treated 
with radiotherapy vs. radical prostatectomy 
Hanlon et al [112] found no difference in
biochemical failure rates between carefully matched
men with and without a family history of prostate
cancer. This supports other studies that failed to show
an increased risk of failure after definitive therapy for
clinically localized prostate cancer in men with either
combined hereditary and familial and patients with the
sporadic form of prostate cancer. 
Chemoprevention trials
Prostate cancer chemoprevention is the
administration of agents that inhibit one or more steps
in prostatic carcinogenesis. The main components of
chemoprevention include agents and their molecular
targets, strategic intermediate endpoint biomarkers and
their critical pathways and cohorts identified by genetic
and acquired risk factors [113]. The identification of
genetic susceptibility loci would enable a group of men
at high risk of developing prostate cancer to be identified
to serve as subjects for chemoprevention trials. If such
trials yield positive results, they potentially could lead to
a recommendation for preventative therapy in genetic
mutation carriers. Several putative chemopreventive
agents are currently being investigated. Results of
a population-based, randomized phase III trial
demonstrates that finasteride may prevent prostate
cancer. However, the paper suggested that only low
grade tumours were prevented and in fact the number
of high grade tumours was greater in the finasteride arm.
Clarke et al [114] studied the impact of supplemental
dietary selenium on the change in the incidence of
prostate cancer. They found that although selenium
shows no protective effects against the primary study
endpoint of squamous and basal cell carcinomas of the
skin, the selenium-treated group in their series had
substantial reductions in the incidence of prostate cancer
as a secondary endpoint. Further studies are clearly
indicated. Preliminary data seem to suggest at least some
benefit with the use of other agents as potential
preventatives in addition to selenium. These include
vitamin E, vitamin D, other 5-alpha-reductase inhibitors,
cyclooxygenase-2 inhibitors, lycopene, and green tea.
Some of these agents are being tested in new large-scale
phase III clinical trials [115]. The Selenium and Vitamin
E Cancer Prevention Trial (SELECT), is an intergroup
phase III clinical trial designed to test the efficacy of
selenium and vitamin E alone and in combination in the
prevention of prostate cancer and aims to build on
secondary analyses of large-scale chemoprevention trials
[116]. The emergence of new powerful tools such as
proteomic analysis of tissue based and secreted proteins
[117] and gene chip cDNA microarrays for multiplex
gene expression profiling would optimise the
identification of new molecular targets, cohorts at risk
and the design of suitable combination trials. 
Targeted screening
Several controversies surround the management of
relatives of prostate cancer patients. Targeted screening
studies have shown a higher percentage of raised PSA
levels in relatives of cases in families compared with
sporadic cases. In a screening study of prostate cancer
in high-risk families done by McWhorter et al [118] it was
shown that previously unsuspected and clinically relevant
cancers were found in 24% of a total of 34 first-degree
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relatives, compared to the approximately 1 (3%) expected
(p<0.01). The study emphasized the importance of
thorough screening in first-degree relatives of prostate
cancer patients. The first targeted screening study based
on BRCA1/2 genotype will start later this year (the
IMPACT study; Tischkowitz and Eeles, 2003) [119].
Targeted screening can be achieved by monitoring serum
PSA levels in relatives of young or early onset prostate
cancer or families with multiple cases. Counselling about
the uncertainties of optimal age at which screening
should be initiated is of paramount importance. The
sub-thirty and sub-forty year old groups would not be
screened by most authorities. Most would start screening
either at age five years younger than youngest age at
diagnosis of a relative or forty years, but not normally
younger than this. 
Proteomics and bioinformatics
With the recent exponential increase in the
development and improvement of techniques involving
proteomics, there has been a dramatic increase in the
likelihood of finding clinically relevant candidate genes,
gene clusters and signalling pathways. This would
potentially extrapolate itself into better diagnostic and/or
more specific targeted therapeutic plans in the
management of sufferers of prostate cancer [119, 120]. 
Summary 
Prostate cancer inheritance following a simple
Mendelian pattern may be identified in the families of
probands with early-onset cases. At present, the only
clinically applicable measure to try to reduce prostate
cancer mortality in families with hereditary disease is
screening, which aims to diagnose the disease when it
is still in a curable stage. The specific mechanism of how
gene mutations contribute to an increased susceptibility
for prostate cancer remains elusive but the finding of
germline mutations in the BRCA2, CHEK2 and NBS1
genes suggest that at least a proportion may occur due
to mutations in the DNA repair pathway. This would have
implications for treatment of such individuals with DNA
damaging agents. It is likely that the cause of the majority
of prostate cancer cases will be multifactorial and will
involve genetic and environmental factors. 
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